3 Lung Cancer Stocks That Could Soar in September
Get ready for some market-moving presentations at the World Conference on Lung Cancer this September. Eli Lilly (NYSE: LLY), Amgen (NASDAQ: AMGN), and AstraZeneca (NYSE: AZN) are scheduled to present hotly anticipated results that could expand their presence in this important niche.
In 2019, the American Cancer Society thinks lung cancer will claim the lives of an estimated 142,670 Americans, and another 228,150 will receive their first diagnosis. These three drugmakers are taking different approaches to boost these awful survival odds. Here's what investors need to know about their progress.
Image source: Getty Images.
Quelle Fool.com
